Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19
Prasenohadi, P.; Burhan, E.; Dhunny, S.; Suharno, W.; Wabnitz, P.; Kim, Y.-W.; Petrosillo, N. Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19. J. Clin. Med. 2022, 11, 2961. https://doi.org/10.3390/jcm11112961
Prasenohadi P, Burhan E, Dhunny S, Suharno W, Wabnitz P, Kim Y-W, Petrosillo N. Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19. Journal of Clinical Medicine. 2022; 11(11):2961. https://doi.org/10.3390/jcm11112961
Chicago/Turabian StylePrasenohadi, Prasenohadi, Erlina Burhan, Sri Dhunny, Wahyuningsih Suharno, Paul Wabnitz, Yoon-Won Kim, and Nicola Petrosillo. 2022. "Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19" Journal of Clinical Medicine 11, no. 11: 2961. https://doi.org/10.3390/jcm11112961